193 related articles for article (PubMed ID: 31837244)
1. Isotretinoin: Still the cause of anxiety for teratogenicity.
Altıntaş Aykan D; Ergün Y
Dermatol Ther; 2020 Jan; 33(1):e13192. PubMed ID: 31837244
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin.
Yook JH; Han JY; Choi JS; Ahn HK; Lee SW; Kim MY; Ryu HM; Nava-Ocampo AA
Clin Toxicol (Phila); 2012 Dec; 50(10):896-901. PubMed ID: 23116253
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
Schaefer C; Meister R; Weber-Schoendorfer C
Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
[TBL] [Abstract][Full Text] [Related]
4. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.
Bérard A; Azoulay L; Koren G; Blais L; Perreault S; Oraichi D
Br J Clin Pharmacol; 2007 Feb; 63(2):196-205. PubMed ID: 17214828
[TBL] [Abstract][Full Text] [Related]
5. A survey of pregnant women using isotretinoin.
Robertson J; Polifka JE; Avner M; Chambers C; Delevan G; Koren G; Lavigne SV; Martinez LP; Miller RK; Carey JC
Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):881-7. PubMed ID: 16228976
[TBL] [Abstract][Full Text] [Related]
6. Teratogenicity of systemic isotretinoin.
Holst H; Muhari-Stark E; Lava SA
Minerva Pediatr; 2018 Feb; 70(1):107-109. PubMed ID: 29363297
[No Abstract] [Full Text] [Related]
7. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential.
AlGhamdi KM; Khurram H; Asiri YA; Mandil A
Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870
[TBL] [Abstract][Full Text] [Related]
8. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of isotretinoin exposure during pregnancy.
Dai WS; LaBraico JM; Stern RS
J Am Acad Dermatol; 1992 Apr; 26(4):599-606. PubMed ID: 1597546
[TBL] [Abstract][Full Text] [Related]
10. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.
Lagan BM; Dolk H; White B; Uges DR; Sinclair M
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556
[TBL] [Abstract][Full Text] [Related]
11. A new perspective on isotretinoin in pregnancy: Pregnancy outcomes, evaluation of complex phenotypes, and importance of teratological counselling.
Alay MT; Kalayci A; Seven M
Eur J Obstet Gynecol Reprod Biol; 2023 Dec; 291():148-155. PubMed ID: 37890418
[TBL] [Abstract][Full Text] [Related]
12. Possible long-term teratogenic effect of isotretinoin in pregnancy.
Malvasi A; Tinelli A; Buia A; De Luca GF
Eur Rev Med Pharmacol Sci; 2009; 13(5):393-6. PubMed ID: 19961047
[TBL] [Abstract][Full Text] [Related]
13. Face-to-face: isotretinoin use and pregnancy outcome.
Tırmıkçıoğlu Z; Tatlıparmak A
Int J Dermatol; 2024 Feb; 63(2):232-238. PubMed ID: 38095245
[TBL] [Abstract][Full Text] [Related]
14. Fetal exposure to isotretinoin-an international problem.
Garcia-Bournissen F; Tsur L; Goldstein LH; Staroselsky A; Avner M; Asrar F; Berkovitch M; Straface G; Koren G; De Santis M
Reprod Toxicol; 2008 Jan; 25(1):124-8. PubMed ID: 18077132
[TBL] [Abstract][Full Text] [Related]
15. Caring for women with childbearing potential taking teratogenic dermatologic drugs. Guidelines for practice.
Perlman SE; Rudy SJ; Pinto C; Townsend-Akpan C
J Reprod Med; 2001 Feb; 46(2 Suppl):153-61. PubMed ID: 11255823
[TBL] [Abstract][Full Text] [Related]
16. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
17. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.
Honein MA; Moore CA; Erickson JD
Drug Saf; 2004; 27(14):1069-80. PubMed ID: 15554743
[TBL] [Abstract][Full Text] [Related]
18. Congenital microtia in a neonate due to maternal isotretinoin exposure 1 month before pregnancy: Case Report.
Shirazi M; Abbariki E; Pirjani R; Akhavan S; Dastgerdy E
J Obstet Gynaecol Res; 2015 Jun; 41(6):975-8. PubMed ID: 25773513
[TBL] [Abstract][Full Text] [Related]
19. Isotretinoin exposure during pregnancy: a population-based study in The Netherlands.
Zomerdijk IM; Ruiter R; Houweling LM; Herings RM; Sturkenboom MC; Straus SM; Stricker BH
BMJ Open; 2014 Nov; 4(11):e005602. PubMed ID: 25392022
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy and neonatal outcomes after periconceptional exposure to isotretinoin in Koreans.
Cha EH; Kim N; Kwak HS; Han HJ; Joo SH; Choi JS; Chun KC; Kim YA; Koh JW; Han JY
Obstet Gynecol Sci; 2022 Mar; 65(2):166-175. PubMed ID: 35193174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
